baricitinib
baricitinib: sourced relationships with 1 company · 35 clinical trials tracked · 1 FDA decision.
baricitinib evidence translation
What we can confirm
1 FDA record · 35 tracked trials
What it means
What to watch
Prepared research question
How could baricitinib → LLY affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 1 study sponsors
Related indications
Study sponsors
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| ELI LILLY & Co (LLY) Reported 2018-05-31 · Current development: unknownSource In collaboration with Incyte Corporation, for the treatment … | Approved |
| ELI LILLY & Co (LLY) Reported 2018-05-31 · Current development: unknownSource for the treatment of adults with moderately to severely acti… | Approved |
Clinical Trial Registry Records (35)showing 10 most recent
A Randomised Platform Trial to Evaluate Therapeutics in Patients With Moderate or Severe Dengue (DEN-HOST)
Primary endpoint: Progression to severe dengue/critical dengue
Baricitinib Curative Repression of HIV-1
Primary endpoint: Time to restart ART
A Phase 1 Open-label, Multiple Dose Study of Upadacitinib, Tofacitinib, and Baricitinib in Healthy Subjects to Evaluate Pharmacodynamic Biomarkers
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAE)
A Phase IIa, Single-Site, Open-Label Trial of Baricitinib in Patients With Cardiac Sarcoidosis
Primary endpoint: Proportion of patients with resolution of cardiac FDG uptake on PET-CT
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Preserve Beta Cell Function in Participants Newly Diagnosed With Type 1 Diabetes Aged ≥1 to <36 Years
Primary endpoint: Change from Baseline in C-peptide Area Under the Curve (AUC)
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Delay Stage 3 Type 1 Diabetes in At-risk Participants Aged ≥1 to <36 Years
Primary endpoint: Time from Baseline to Diagnosis of Stage 3 Type 1 Diabetes
Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica - JADORE-BARI Study
Primary endpoint: Following of the Polymyalgia Rheumatica Activity score
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Adult Patients of African Descent With Biopsy-proven Central Centrifugal Cicatricial Alopecia (CCCA)
Primary endpoint: Change from Baseline in Investigator Global Assessment Score at Month 12
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID (REVERSE-LC)
Primary endpoint: CNS-Vital Signs Global Cognitive Index
A Pilot Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)
Primary endpoint: 30% Change in Lichen Planopilaris Activity (LPPAI) Scores
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with baricitinib?
baricitinib has dated SEC/FDA relationship records for ELI LILLY & Co.
How many clinical trials involve baricitinib?
BioSniper tracks 35 clinical trials involving baricitinib.
What is baricitinib's latest FDA decision?
The most recent tracked FDA decision for baricitinib is Approval for 1 INDICATIONS AND USAGE OLUMIANT ® is a Janus kinase (JAK) inhibitor indicated for: the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers. ( 1.1 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO. ( 1.2 ) the treatment of adult patients with severe alopecia areata. ( 1.3 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants. ( 1.3 ) 1.1 Rheumatoid Arthritis OLUMIANT ® (baricitinib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) blockers. Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine. 1.2 Coronavirus Disease 2019 (COVID-19) OLUMIANT is indicated for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). 1.3 Alopecia Areata OLUMIANT is indicated for the treatment of adult patients with severe alopecia areata. Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants., dated May 31, 2018.